The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Virus Inactivation

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Virus Inactivation


High impact information on Virus Inactivation

  • APOBEC3G deaminates deoxycytidines in minus strand DNA to deoxyuridines, resulting in G to A hypermutation and viral inactivation [6].
  • HBV may therefore be particularly vulnerable to the capsid-targeted viral inactivation approach [7].
  • Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab [8].
  • Furthermore, transmission of B19 infection was observed, indicating presence of the infectious virus despite routine viral inactivation/removal procedures during the manufacturing process [9].
  • Pretreatment of cells with compound prior to addition of virus also demonstrated strong microbicidal activity with dextran sulfate and polystyrene sulfonate, but cellulose sulfate required several orders of magnitude more compound for virus inactivation [10].

Chemical compound and disease context of Virus Inactivation


Biological context of Virus Inactivation


Anatomical context of Virus Inactivation


Associations of Virus Inactivation with chemical compounds


Gene context of Virus Inactivation

  • We have investigated the effect of virus inactivation procedures on FVIII function by preparing experimental concentrates from the same starting cryoprecipitate with the following procedures: none (N); dry heat (DH); pasteurisation (P); solvent/detergent (SD); solvent detergent + dry heat (SDDH); solvent detergent + pasteurisation (SDP) [26].
  • Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods [27].
  • The generation of hmw TNF alpha mRNA required exposure to fully infectious influenza A virus, since virus inactivation at 56 degrees C induced only regular and not hmw TNF alpha mRNA [28].
  • STUDY DESIGN AND METHODS: Virus inactivation was monitored by decrease of infectivity and loss of capsid integrity [29].
  • Methylene blue (MB), riboflavin (RB) and psoralen sensitizers (4' aminomethyl-4,5',8-trimethylpsoralen [AMT] and derivatives) are under study as sensitizers of viral inactivation of blood products such as plasma proteins, platelets and red cells, all of which lack genomic nucleic acid [30].

Analytical, diagnostic and therapeutic context of Virus Inactivation


  1. Viral inactivation of vesicular stomatitis virus in normal human serum by cross-linked polyvinylpyrrolidone. Highsmith, F.A., Caple, M., Walthall, B., Shanbrom, E., Drohan, W.N. J. Infect. Dis. (1993) [Pubmed]
  2. Comparative study of mechanisms of herpes simplex virus inactivation by sodium lauryl sulfate and n-lauroylsarcosine. Piret, J., Roy, S., Gagnon, M., Landry, S., Désormeaux, A., Omar, R.F., Bergeron, M.G. Antimicrob. Agents Chemother. (2002) [Pubmed]
  3. Reduction of 4-nitroquinoline 1-oxide to 4-hydroxyaminoquinoline 1-oxide in lysates of cytomegalovirus-infected cells. Speelman, D.J., Lund, H., Culling, A., Kittredge, J.S., Williams, B.J., Albrecht, T. J. Gen. Virol. (1983) [Pubmed]
  4. Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. García, C.C., Djavani, M., Topisirovic, I., Borden, K.L., Salvato, M.S., Damonte, E.B. J. Gen. Virol. (2006) [Pubmed]
  5. Hepatitis C virus RNA in factor VIII concentrates. Guo, Z.P., Yu, M.W. Transfusion (1995) [Pubmed]
  6. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. Svarovskaia, E.S., Xu, H., Mbisa, J.L., Barr, R., Gorelick, R.J., Ono, A., Freed, E.O., Hu, W.S., Pathak, V.K. J. Biol. Chem. (2004) [Pubmed]
  7. Significant interference with hepatitis B virus replication by a core-nuclease fusion protein. Beterams, G., Nassal, M. J. Biol. Chem. (2001) [Pubmed]
  8. Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Reed, D.J., Lin, X., Thomas, T.D., Birks, C.W., Tang, J., Rother, R.P. J. Immunol. (1997) [Pubmed]
  9. Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Schneider, B., Becker, M., Brackmann, H.H., Eis-Hübinger, A.M. Thromb. Haemost. (2004) [Pubmed]
  10. Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Christensen, N.D., Reed, C.A., Culp, T.D., Hermonat, P.L., Howett, M.K., Anderson, R.A., Zaneveld, L.J. Antimicrob. Agents Chemother. (2001) [Pubmed]
  11. The role of DNA damage in PM2 viral inactivation by methylene blue photosensitization. Specht, K.G. Photochem. Photobiol. (1994) [Pubmed]
  12. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety. Herring, S.W., Abildgaard, C., Shitanishi, K.T., Harrison, J., Gendler, S., Heldebrant, C.M. J. Lab. Clin. Med. (1993) [Pubmed]
  13. Antiviral and hemolytic activities of surfactin isoforms and their methyl ester derivatives. Kracht, M., Rokos, H., Ozel, M., Kowall, M., Pauli, G., Vater, J. J. Antibiot. (1999) [Pubmed]
  14. Inactivation of poliovirus with beta-propiolactone. Jiang, S.D., Pye, D., Cox, J.C. Journal of biological standardization. (1986) [Pubmed]
  15. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products. Roberts, P. Biologicals (2000) [Pubmed]
  16. Molecular approaches to validate disinfectants against human hepatitis B virus. Jursch, C.A., Gerlich, W.H., Glebe, D., Schaefer, S., Marie, O., Thraenhart, O. Med. Microbiol. Immunol. (Berl.) (2002) [Pubmed]
  17. In vitro fluence rate effects in photodynamic reactions with AIPcS4 as sensitizer. Moor, A.C., Lagerberg, J.W., Tijssen, K., Foley, S., Truscott, T.G., Kochevar, I.E., Brand, A., Dubbelman, T.M., VanSteveninck, J. Photochem. Photobiol. (1997) [Pubmed]
  18. Large-scale preparation of highly purified human C1-inhibitor for therapeutic use. Poulle, M., Burnouf-Radosevich, M., Burnouf, T. Blood Coagul. Fibrinolysis (1994) [Pubmed]
  19. Photodynamic virus inactivation of thrombocyte concentrates by phenothiazine dyes. Klein-Struckmeier, A., Mohr, H. Beiträge zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine. (1997) [Pubmed]
  20. Depression of early protection against influenza virus infection by cyclophosphamide and its restoration by Y-19995 [2,4'-bis(1-methyl-2-dimethyl-aminoethoxyl)-3-benzoylpyridine dimaleate]. Tsuru, S., Shinomiya, N., Nomoto, K. Nat. Immun. Cell Growth Regul. (1991) [Pubmed]
  21. Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene. Schinazi, R.F., Sijbesma, R., Srdanov, G., Hill, C.L., Wudl, F. Antimicrob. Agents Chemother. (1993) [Pubmed]
  22. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Atance, R., Pereira, A., Ramírez, B. Transfusion (2001) [Pubmed]
  23. Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination. Riggert, J., Humpe, A., Legler, T.J., Wolf, C., Simson, G., Köhler, M. Transfusion (2001) [Pubmed]
  24. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation. Omar, A., Kempf, C., Immelmann, A., Rentsch, M., Morgenthaler, J.J. Transfusion (1996) [Pubmed]
  25. Virus inactivation in red cell concentrates by photosensitization with phthalocyanines: protection of red cells but not of vesicular stomatitis virus with a water-soluble analogue of vitamin E. Ben-Hur, E., Rywkin, S., Rosenthal, I., Geacintov, N.E., Horowitz, B. Transfusion (1995) [Pubmed]
  26. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Raut, S., Di Giambattista, M., Bevan, S.A., Hubbard, A.R., Barrowcliffe, T.W., Laub, R. Thromb. Haemost. (1998) [Pubmed]
  27. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. Goudemand, J., Scharrer, I., Berntorp, E., Lee, C.A., Borel-Derlon, A., Stieltjes, N., Caron, C., Scherrmann, J.M., Bridey, F., Tellier, Z., Federici, A.B., Mannucci, P.M. J. Thromb. Haemost. (2005) [Pubmed]
  28. Infection of macrophages by influenza A virus: characteristics of tumour necrosis factor-alpha (TNF alpha) gene expression. Lehmann, C., Sprenger, H., Nain, M., Bacher, M., Gemsa, D. Res. Virol. (1996) [Pubmed]
  29. Different susceptibility of B19 virus and mice minute virus to low pH treatment. Boschetti, N., Niederhauser, I., Kempf, C., Stühler, A., Löwer, J., Blümel, J. Transfusion (2004) [Pubmed]
  30. Binding affinities of commonly employed sensitizers of viral inactivation. Dardare, N., Platz, M.S. Photochem. Photobiol. (2002) [Pubmed]
  31. Leucocytes can be eliminated from plasma by filtration prior to viral inactivation with methylene blue. Rider, J.R., Winter, M.A., Payrat, J.M., Mathias, J.M., Pamphilon, D.H. Vox Sang. (1998) [Pubmed]
  32. Chemical inactivation of hepatitis B virus: the effect of disinfectants on virus-associated DNA polymerase activity, morphology and infectivity. Howard, C.R., Dixon, J., Young, P., van Eerd, P., Schellekens, H. J. Virol. Methods (1983) [Pubmed]
  33. A new method of purifying fibrinogen with both biological and immunological activity from human plasma. Okuda, M., Uemura, Y., Tatsumi, N. Prep. Biochem. Biotechnol. (2003) [Pubmed]
WikiGenes - Universities